Research Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trial Meg J Jardine, Sradha S Kotwal, Abhinav Bassi, et al BMJ 2022; 379 doi: https://doi.org/10.1136/bmj-2022-072175 (Published 16 November 2022)Cite this as: BMJ 2022;379:e072175 Abstract Objective To determine whether disrupting the renin angiotensin system with angiotensin receptor blockers will improve clinical out...

ARTICLES| VOLUME 10, ISSUE 11, P1061-1073, NOVEMBER 01, 2022 Onset and window of SARS-CoV-2 infectiousness and temporal correlation with symptom onset: a prospective, longitudinal, community cohort study Seran Hakki, Jie Zhou, Jakob Jonnerby, et al Lancet Respir Med 2022; 10: 1061-1073 Published:August 18, 2022 DOI:https://doi.org/10.1016/S2213-2600(22)00226-0 Summary Background Knowledge of the window of SARS-CoV-2 infectiousness is cr...

ARTICLES| VOLUME 10, ISSUE 11, P1038-1048, NOVEMBER 01, 2022 Incidence of death or disability at 6 months after extracorporeal membrane oxygenation in Australia: a prospective, multicentre, registry-embedded cohort study Carol L Hodgson, Alisa M Higgins, Michael J Bailey, et al Lancet Respir Med Published:September 26, 2022 DOI:https://doi.org/10.1016/S2213-2600(22)00248-X Summary Background Extracorporeal membrane oxygenation (ECMO) is...

ARTICLES| VOLUME 22, ISSUE 11, P1626-1647, NOVEMBER 01, 2022 Age–sex differences in the global burden of lower respiratory infections and risk factors, 1990–2019: results from the Global Burden of Disease Study 2019 GBD 2019 LRI Collaborators Lancet Infect Dis 2022; 11: 1626-1647 Published:August 11, 2022 DOI:https://doi.org/10.1016/S1473-3099(22)00510-2 Summary Background The global burden of lower respiratory infections (LRIs) and cor...

ARTICLES| VOLUME 10, ISSUE 11, P1074-1085, NOVEMBER 01, 2022 Daily use of lateral flow devices by contacts of confirmed COVID-19 cases to enable exemption from isolation compared with standard self-isolation to reduce onward transmission of SARS-CoV-2 in England: a randomised, controlled, non-inferiority trial Nicola K Love, Derren R Ready, Charlie Turner, et al. Lancet Respir Med 2022; 10: 1074-1085 DOI:https://doi.org/10.1016/S2213-2600(22)002...

ORIGINAL ARTICLE Liquefied Petroleum Gas or Biomass for Cooking and Effects on Birth Weight Thomas F. Clasen, Howard H. Chang, Lisa M. Thompson, et al N Engl J Med 2022; 387:1735-1746DOI: 10.1056/NEJMoa2206734 Abstract BACKGROUND Exposure during pregnancy to household air pollution caused by the burning of solid biomass fuel is associated with adverse health outcomes, including low birth weight. Whether the replacement of a biomass cookstove with a lique...

ORIGINAL ARTICLE Lifting Universal Masking in Schools — Covid-19 Incidence among Students and Staff Tori L. Cowger, Eleanor J. Murray, Jaylen Clarke, et al N Engl J Med 2022; 387:1935-1946DOI: 10.1056/NEJMoa2211029 Abstract BACKGROUND In February 2022, Massachusetts rescinded a statewide universal masking policy in public schools, and many Massachusetts school districts lifted masking requirements during the subsequent weeks. In the greater Boston a...

ORIGINAL ARTICLE Progression of Atrial Fibrillation after Cryoablation or Drug Therapy Jason G. Andrade, Marc W. Deyell, Laurent Macle, et al N Engl J Med November 7, 2022DOI: 10.1056/NEJMoa2212540 Abstract BACKGROUND Atrial fibrillation is a chronic, progressive disorder, and persistent forms of atrial fibrillation are associated with increased risks of thromboembolism and heart failure. Catheter ablation as initial therapy may modify the pathogenic mec...

ORIGINAL ARTICLE Defibrillation Strategies for Refractory Ventricular Fibrillation Sheldon Cheskes, P. Richard Verbeek, Ian R. Drennan, et al N Engl J Med November 6, 2022DOI: 10.1056/NEJMoa2207304 Abstract BACKGROUND Despite advances in defibrillation technology, shock-refractory ventricular fibrillation remains common during out-of-hospital cardiac arrest. Double sequential external defibrillation (DSED; rapid sequential shocks from two defibrillators)...

ORIGINAL ARTICLE Once-Weekly Semaglutide in Adolescents with Obesity Daniel Weghuber, Timothy Barrett, Margarita Barrientos-Pérez, et al N Engl J Med November 2, 2022DOI: 10.1056/NEJMoa2208601 Abstract BACKGROUND A once-weekly, 2.4-mg dose of subcutaneous semaglutide, a glucagon-like peptide-1 receptor agonist, is used to treat obesity in adults, but assessment of the drug in adolescents has been lacking. METHODS In this double-blind, parallel-grou...